Eli Lilly cut its outlook for fourth-quarter revenue citing sluggish growth in the market for incretin, which increases insulin levels.
Related Posts
Universal Music Sheds $16 Billion in Market Cap After Revenues Disappoint
The record label behind Taylor Swift, Billie Eilish and Ariana Grande posted revenue growth from subscriptions and streaming services well below what analysts had expected.
NASA to Assign Lunar Delivery Missions to SpaceX and Blue Origin
The agency says the companies would supply landers that would carry equipment and infrastructure to the moon’s surface.
Auto & Transport Roundup: Market Talk
Find insight on Nikola, European car makers and more in the latest Market Talks covering the auto and transport sector.